全文获取类型
收费全文 | 208591篇 |
免费 | 3009篇 |
国内免费 | 160篇 |
专业分类
耳鼻咽喉 | 1605篇 |
儿科学 | 7404篇 |
妇产科学 | 3607篇 |
基础医学 | 20456篇 |
口腔科学 | 2180篇 |
临床医学 | 15548篇 |
内科学 | 38754篇 |
皮肤病学 | 1061篇 |
神经病学 | 19562篇 |
特种医学 | 10227篇 |
外国民族医学 | 1篇 |
外科学 | 34677篇 |
综合类 | 2522篇 |
一般理论 | 18篇 |
预防医学 | 20002篇 |
眼科学 | 3177篇 |
药学 | 11352篇 |
中国医学 | 668篇 |
肿瘤学 | 18939篇 |
出版年
2023年 | 205篇 |
2022年 | 395篇 |
2021年 | 891篇 |
2020年 | 544篇 |
2019年 | 893篇 |
2018年 | 22866篇 |
2017年 | 18009篇 |
2016年 | 20132篇 |
2015年 | 1786篇 |
2014年 | 2114篇 |
2013年 | 2538篇 |
2012年 | 9516篇 |
2011年 | 23639篇 |
2010年 | 20308篇 |
2009年 | 12952篇 |
2008年 | 21754篇 |
2007年 | 24071篇 |
2006年 | 2891篇 |
2005年 | 4430篇 |
2004年 | 5401篇 |
2003年 | 6232篇 |
2002年 | 4191篇 |
2001年 | 526篇 |
2000年 | 564篇 |
1999年 | 389篇 |
1998年 | 580篇 |
1997年 | 505篇 |
1996年 | 305篇 |
1995年 | 319篇 |
1994年 | 275篇 |
1993年 | 231篇 |
1992年 | 131篇 |
1991年 | 192篇 |
1990年 | 207篇 |
1989年 | 151篇 |
1988年 | 110篇 |
1987年 | 95篇 |
1986年 | 80篇 |
1985年 | 97篇 |
1984年 | 105篇 |
1983年 | 108篇 |
1982年 | 108篇 |
1981年 | 80篇 |
1980年 | 105篇 |
1979年 | 39篇 |
1978年 | 45篇 |
1974年 | 42篇 |
1938年 | 60篇 |
1932年 | 57篇 |
1930年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
112.
113.
Marc Ziegler Alexandre Castro-Caldas Susanna Del Signore Olivier Rascol 《Movement disorders》2003,18(4):418-425
Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. 相似文献
114.
Robert G. Frank Allyson E. Haut Megan Smick Marc W. Haut John M. Chaney 《Brain injury : [BI]》1990,4(3):289-295
Cognitive deficits associated with closed head injury (CHI) have been well studied. Less attention has been directed to the emotional consequences of CHI and subsequent attempts to cope with major life events. CHI typically constitutes a catastrophic injury, yet few studies have examined coping strategies used by individuals after CHI or the effects of CHI on family functioning that may mediate coping. Previous workers have speculated that time since injury is a crucial determinant of coping; however, this has not been investigated with regard to CHI. In this preliminary investigation, 40 patients with CHI were compared with 17 neurologically intact controls. The CHI group was divided into two groups according to time since injury. It was found that patients with CHI used information seeking as their most dominant coping strategy regardless of their time since injury. Patients with CHI had higher family cohesion scores than control subjects. Implications of these findings for psychological response to CHI are discussed. 相似文献
115.
M.D.Robert R. Bahnson M.D.B. Simon Slasky M.D.Marc S. Ernstoff M.D.Barbara F. Banner 《Urology》1990,35(6)
The ultrasonographic characteristics of an epidermoid cyst of the testicle are presented. Since these, findings are similar to other published case reports, preoperative sonographic diagnosis of this lagon may be possible. 相似文献
116.
Gunter Deppe M.D. Marc L. Kahn M.D. Vinay K. Malviya M.D. John M. Malone Jr. M.D. Carl W. Christensen M.D. Ph.D. 《Gynecologic oncology》1996,62(3):340-343
Experience with the P.A.S.-PORT, a peripherally implanted central venous access device, is evaluated in a retrospective review of 154 patients from July 1991 to June 1994. Blood could not be aspirated from six patients. Complications included temporary minor thrombophlebitis in seven patients (4.5%), symptomatic axillary or subclavian vein thrombosis in five patients (3.2%), clotted port in two patients (1.2%), port pocket cellulitis in two patients (1.2%), and fungal sepsis in two patients (1.2%). In six patients (3.8%) the P.A.S.-PORT had to be removed because of complications. The P.A.S.-PORT facilitated delivery of chemotherapy, parenteral nutrition, blood products, antibiotics, hydration, and blood sampling. It was demonstrated that the P.A.S.-PORT may be inserted and used with a low incidence of complications in gynecologic cancer patients. 相似文献
117.
G. Vacca E. Marano V. Brescia Morra R. Lanzillo M. De Vito E. Parente G. Orefice 《Neurological sciences》2007,28(3):133-135
The prevalence of primary headache (PH) in a multiple sclerosis (MS) sample vs. control healthy subjects was investigated at a neurological clinic in 2004–2005: 122 of 238 (51%) MS patients and 57 of
238 (23%) controls proved to be affected by headache. The groups did not differ for the rates of PH types. Headache types
of MS patients were comparable to those of PH patients that were observed at the same institute in a case-control comparison.
First symptoms of headache preceded those of MS in two thirds of cases. Headache features did not significantly change after
MS onset. Comorbidity of MS and PH could be explained by some common clinical and biological traits. 相似文献
118.
Volker Heinemann 《Breast cancer research and treatment》2003,81(1):43-48
Single-agent chemotherapy of metastatic breast cancer is the treatment of choice in patients with slow tumor progression and asymptomatic disease. In this patient group, the choice of drugs is based more on good tolerability than on efficacy. By contrast, symptomatic or rapidly progressing disease requires the use of highly active regimens where more weight is put on reliable antitumor activity. While anthraycline-based combination regimens have set the standard of effective treatment, the addition of docetaxel (and to a lesser extent paclitaxel) has improved tumor response, but failed to induce a consistent prolongation of survival. Based on retrospective analyses, it is hypothesised that the combined use of anthracyclines and taxanes in first-line therapy may be most beneficial in defined subgroups: after adjuvant chemotherapy, in patients with HER-2 gene amplification, possibly also in patients with rapidly progressing visceral disease. 相似文献
119.
120.
Ohne Zusammenfassung 相似文献